Trump Action Archive

Supporting reports

• Trump proclamation imposes 100% tariffs on patented pharmaceuticals and APIs, with reduced rates for companies committing to domestic production and MFN pricing agreements. — President Trump issued Proclamation 11020 invoking Section 232 of the Trade Expansion Act, determining that imports of patented pharmaceuticals and active pharmaceutical ingredients threaten U.S. national security due to heavy reliance on foreign production (53% of patented drugs, 85% of APIs). The proclamation imposes a 100% ad valorem duty on patented pharmaceuticals and APIs effective July 31, 2026, with reduced rates (20% declining to 100% over four years, or zero) for companies with approved onshoring plans or MFN pricing agreements. Generic pharmaceuticals are exempted. The Secretaries of Commerce and Health and Human Services are directed to negotiate agreements addressing the supply chain vulnerability.
• Trump proclamation strengthens metal tariffs, expands scope to full customs value, raises rates to 50 percent for aluminum and steel. — President Trump issued Proclamation 11021 on April 2, 2026, modifying tariff regimes on aluminum, steel, and copper imports established under Section 232 of the Trade Expansion Act of 1962. The proclamation expands tariffs to apply to the full customs value of metal articles and derivatives, regardless of metal content. Primary tariff rates are set at 50 percent for most aluminum and steel articles and certain copper articles, with 25 percent rates for other copper and derivative articles. Reduced rates of 10–15 percent apply to products from the United Kingdom and articles made entirely from U.S.-origin metals. The proclamation terminates prior derivative-inclusion processes and authorizes the Secretary of Commerce and U.S. Trade Representative to add derivative articles on a rolling basis. Effective April 6, 2026.
• Trump threatens 100% tariff on pharmaceutical companies refusing pricing deals — Donald Trump announced an executive order threatening 100% tariffs on branded pharmaceutical drugs and active ingredients from companies that do not strike pricing agreements with the White House or increase domestic manufacturing. Generic drugs are exempted for at least one year. Large companies have 120 days and smaller companies 180 days to negotiate deals; 17 drugmakers have already secured exemptions. The policy aims to pressure drugmakers to lower US prices to levels comparable with other high-income countries.
• Trump issues executive order imposing tariffs on pharmaceutical imports under Section 232 national security authority — President Trump issued an executive order on April 2, 2026, imposing a 100 percent ad valorem tariff on imported patented pharmaceuticals and active pharmaceutical ingredients (APIs), effective July 31, 2026 for listed companies and September 29, 2026 for others. The order provides reduced tariff rates (20 percent, 15 percent, or zero) for companies with approved onshoring plans, those in trade agreements with specific countries (EU, Japan, Korea, Switzerland, UK), or those entering MFN pricing agreements. Generic pharmaceuticals are excluded from tariffs. The Secretary of Commerce and HHS are directed to negotiate agreements to address alleged national security threats from pharmaceutical import dependence.
• President Trump issued proclamation modifying tariff regimes on aluminum, steel, and copper imports — President Trump signed Proclamation 10963 on April 2, 2026, modifying tariffs on aluminum, steel, and copper imports under Section 232 of the Trade Expansion Act of 1962. The proclamation directs that ad valorem tariffs apply to the full customs value of metal articles and derivatives, effective April 6, 2026. Primary rates are set at 50 percent for most aluminum and steel articles and certain copper articles, with 25 percent rates for other copper and derivative articles. Reduced rates of 25 percent and 15 percent apply to United Kingdom products, and 10 percent rates apply to articles made entirely from U.S.-origin metals. The proclamation terminates prior derivative-inclusion processes and authorizes the Secretary of Commerce and U.S. Trade Representative to add derivative articles on a rolling basis. Russia-origin aluminum remains subject to 200 percent duties. The order directs monitoring and a 90-day status update.
• Trump issued proclamation imposing tariffs on patented pharmaceuticals and pharmaceutical ingredients under Section 232 national security authority — President Trump signed a proclamation on April 2, 2026, invoking Section 232 of the Trade Expansion Act of 1962 to impose tariffs on patented pharmaceuticals and pharmaceutical ingredients. The proclamation imposes a 100 percent ad valorem duty on most patented drugs and APIs, with reduced rates (20 percent, 15 percent, or zero) for companies meeting onshoring, pricing agreement, or trade framework conditions. The order directs the Secretaries of Commerce and Health and Human Services to negotiate agreements within 90 days and exempts generic pharmaceuticals, orphan drugs, and certain specialty products from tariffs.
• White House issued fact sheet on strengthened tariffs for steel, aluminum, and copper imports — The White House published a fact sheet on April 2, 2026, describing a proclamation signed by President Trump that restructures tariffs on imported steel, aluminum, and copper. The fact sheet states the proclamation establishes tiered tariff rates: 50% on articles made entirely or almost entirely of these metals; 25% on derivative articles substantially composed of them; 15% on certain industrial and electrical grid equipment through 2027; 10% on products made abroad entirely with American metals; and exempts products containing 15% or less of these metals. The fact sheet claims the tariffs protect national security and domestic manufacturing, citing new steelmaking capacity and smelting operations announced or underway.
• White House issued fact sheet promoting pharmaceutical tariffs under Section 232 — The White House issued a fact sheet on April 2, 2026, promoting tariffs imposed by President Trump on patented pharmaceutical products and ingredients under Section 232 of the Trade Expansion Act of 1962. The fact sheet states a 100% base tariff applies, with reduced rates (15%) for trade-deal countries, 0% for companies entering onshoring and MFN pricing agreements with HHS and Commerce, and 20% for onshoring-only agreements. Generic drugs and certain specialty products are exempt. The fact sheet claims the tariffs have already spurred approximately $400 billion in investment commitments.